NASDAQ:CNTG Centogene (CNTG) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free CNTG Stock Alerts $0.43 -0.01 (-2.91%) (As of 03:52 PM ET) Add Compare Share Share Today's Range$0.43▼$0.4650-Day Range$0.43▼$0.9352-Week Range$0.41▼$1.98Volume64,547 shsAverage Volume48,559 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$1.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Centogene alerts: Email Address Centogene MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside243.6% Upside$1.50 Price TargetShort InterestHealthy0.05% of Float Sold ShortDividend StrengthN/ASustainability-1.26Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.25 out of 5 stars 2.0 Analyst's Opinion Amount of Analyst CoverageCentogene has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.05% of the float of Centogene has been sold short.Short Interest Ratio / Days to CoverCentogene has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Centogene has recently decreased by 47.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCentogene does not currently pay a dividend.Dividend GrowthCentogene does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCentogene has received a 70.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Non-invasive prenatal testing services", and "Private medical screening services" products. See details.Environmental SustainabilityThe Environmental Impact score for Centogene is -1.26. Previous Next N/A News and Social Media Coverage Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Centogene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.93% of the stock of Centogene is held by insiders.Percentage Held by InstitutionsOnly 9.94% of the stock of Centogene is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioCentogene has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Centogene Stock (NASDAQ:CNTG)Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight report services. In addition, it offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.Read More CNTG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNTG Stock News HeadlinesApril 4, 2024 | investing.comCentogene faces Nasdaq delisting over share priceApril 2, 2024 | globenewswire.comCENTOGENE Receives Nasdaq Non-Compliance NoticeMay 6, 2024 | Lear Capital (Ad)Dollar CancelledDon’t wait to protect your hard-earned savings. Top economists and billionaires are predicting that the dollar could collapse before the end of 2024.March 22, 2024 | fool.comCentogene (NASDAQ: CNTG)March 19, 2024 | globenewswire.comCENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage DisordersMarch 1, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRa DeficiencyFebruary 29, 2024 | it.investing.comCENTOGENE scopre la carenza del recettore alfa delle cellule pre-TFebruary 29, 2024 | globenewswire.comCENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα DeficiencyMay 6, 2024 | Lear Capital (Ad)Dollar CancelledDon’t wait to protect your hard-earned savings. Top economists and billionaires are predicting that the dollar could collapse before the end of 2024.February 28, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Explores Strategic AlternativesFebruary 28, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a HearingFebruary 28, 2024 | markets.businessinsider.comCentogene Explores Strategic Alternatives, Incl. SaleFebruary 28, 2024 | markets.businessinsider.comCentogene Announces Receipt Of Nasdaq Notice Of DelistingFebruary 28, 2024 | msn.comCentogene to explores strategic alternatives, gets Nasdaq delisting notice; shares plungeFebruary 28, 2024 | globenewswire.comCENTOGENE Explores Strategic AlternativesFebruary 28, 2024 | globenewswire.comCENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a HearingJanuary 25, 2024 | finanznachrichten.deCentogene NV: CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research CollaborationJanuary 25, 2024 | finance.yahoo.comCENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research CollaborationJanuary 24, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Receives French Research Tax Credit AccreditationJanuary 23, 2024 | finance.yahoo.comCENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using MultiomicsJanuary 18, 2024 | finance.yahoo.comCENTOGENE Announces Preliminary Full Year 2023 RevenueDecember 21, 2023 | morningstar.comCentogene NV Ordinary Shares CNTGDecember 13, 2023 | finanznachrichten.deCentogene NV: CENTOGENE's Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment MilestoneDecember 13, 2023 | msn.comMotus GI, C4 Therapeutics among healthcare moversDecember 13, 2023 | msn.comCCCC, XPOF and AUVI are among pre market gainersDecember 13, 2023 | finance.yahoo.comCENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment MilestoneNovember 28, 2023 | finanznachrichten.deCentogene NV: CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture TransactionSee More Headlines Receive CNTG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Centogene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/24/2021Today5/06/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:CNTG CUSIPN/A CIK1757097 Webwww.centogene.com Phone38180113500FaxN/AEmployees444Year FoundedN/APrice Target and Rating Average Stock Price Target$1.50 High Stock Price Target$1.50 Low Stock Price Target$1.50 Potential Upside/Downside+243.6%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$50.03 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book1.51Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.67 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Kim Stratton (Age 62)CEO & Member of Management Board Comp: $933.13kMr. Jose Miguel Coego RiosCFO, Legal & IT and Member of Management BoardDr. Peter Bauer M.D. (Age 54)Chief Medical & Genomic Officer and Member of Management Board Comp: $186.41kDr. Andrin Oswald M.D. (Age 52)Ph.D., Advisor Comp: $943.96kMr. Ian RentschChief Commercial Officer & GM of PharmaKey CompetitorsPsychemedicsNASDAQ:PMDBioNexus Gene LabNASDAQ:BGLCOpGenNASDAQ:OPGNDermTechNASDAQ:DMTKExagenNASDAQ:XGNView All Competitors CNTG Stock Analysis - Frequently Asked Questions What is Centogene's stock price target for 2024? 0 Wall Street research analysts have issued 12-month price targets for Centogene's shares. Their CNTG share price targets range from $1.50 to $1.50. On average, they anticipate the company's stock price to reach $1.50 in the next year. This suggests a possible upside of 243.6% from the stock's current price. View analysts price targets for CNTG or view top-rated stocks among Wall Street analysts. How have CNTG shares performed in 2024? Centogene's stock was trading at $1.20 at the beginning of 2024. Since then, CNTG shares have decreased by 63.6% and is now trading at $0.4365. View the best growth stocks for 2024 here. Are investors shorting Centogene? Centogene saw a decline in short interest in April. As of April 15th, there was short interest totaling 6,200 shares, a decline of 47.9% from the March 31st total of 11,900 shares. Based on an average daily trading volume, of 57,700 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the company's stock are short sold. View Centogene's Short Interest. When is Centogene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our CNTG earnings forecast. How were Centogene's earnings last quarter? Centogene (NASDAQ:CNTG) announced its quarterly earnings results on Wednesday, November, 24th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.49. The business had revenue of $35.60 million for the quarter, compared to analyst estimates of $31.91 million. During the same quarter in the previous year, the company posted ($0.32) EPS. What other stocks do shareholders of Centogene own? Based on aggregate information from My MarketBeat watchlists, some companies that other Centogene investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Alimera Sciences (ALIM), AngloGold Ashanti (AU), Chimerix (CMRX) and Entasis Therapeutics (ETTX). When did Centogene IPO? Centogene (CNTG) raised $60 million in an initial public offering on Thursday, November 7th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Evercore ISI acted as the underwriters for the IPO and Baird and BTIG were co-managers. How do I buy shares of Centogene? Shares of CNTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNTG) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldAI “wealth window” is closing June 25thParadigm PressMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldDollar CancelledLear CapitalHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centogene Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
